LETTERS

Delayed orchidopexy: failure of screening or ascending testis

S Thayil, M Shenoy, K Agrawal
Department of Paediatrics, North Tees and Hartlepool NHS Trust, UK; suchints@hotmail.com
doi: 10.1136/adc.2003.045070

References

Is it time for a European formulary of paediatric medicines?

All Italian physicians, nurses, and pharmacists have recently received, free of charge, the Guida all’uso dei farmaci per i bambini (Guide to the use of drugs for children).1 Considering the number of health professionals involved (about 600,000), the methodology followed, the completeness of the contents, the size of the book produced, and its free availability, this initiative, set up under the auspices of the Italian Ministry of Health, is unique in terms of national and international levels. This formulary can be considered a useful resource for planning new studies, promoting communication and collaboration among researchers, facilitating patient access and recruitment into trials, preventing trial duplication and inappropriate funding, and delivering therapeutic care to children should remain neglected.1 The Sixth Framework Programme is currently running and “Medicines for children” is one of the specific topics. In 2004, the European Commission published a draft consultation document, Regulation of the European Parliament and Council on medicinal products for paediatric use, which is currently undergoing final revisions.

The inevitable use of deduction as a means to obtain what is “probably” the best therapy for a child may gradually disappear, but the continued production and availability of evidence-based information for health professionals and lay people has to be guaranteed. Children have the same rights as adults to receive safe and effective medicines. In such a context, guiding clinicians to ensure that children benefit from the medications they receive is a priority area of the latter has been better defined through numerous studies.2 Off-label/unlicensed prescription rates are in the range 23–62% in European paediatric hospital wards, 55–80% in neonatal intensive care units, and could be as high as 90% in the community setting.3 Wide differences in therapeutic approaches were found between and within settings and countries, suggesting the need for “harmonisation” in clinical practice.

Paediatric studies are more difficult than adult studies because of ethical, practical, and economic considerations. Attempts to improve the situation in Europe were initiated in 1997 when the Committee for Proprietary Medicinal Products (CPMP), part of the European Agency for the Evaluation of Medicinal Products (EMEA), published the “Note for guidance on clinical investigation (section III) medicinal products in the treatment of children”. This note, and the latter has been better defined through numerous studies.3 Off-label/unlicensed prescription rates are in the range 23–62% in European paediatric hospital wards, 55–80% in neonatal intensive care units, and could be as high as 90% in the community setting.3 Wide differences in therapeutic approaches were found between and within settings and countries, suggesting the need for “harmonisation” in clinical practice.

Paediatric studies are more difficult than adult studies because of ethical, practical, and economic considerations. Attempts to improve the situation in Europe were initiated in 1997 when the Committee for Proprietary Medicinal Products (CPMP), part of the European Agency for the Evaluation of Medicinal Products (EMEA), published the “Note for guidance on clinical investigation (section III) medicinal products in the treatment of children”. This note, and the latter has been better defined through numerous studies.3 Off-label/unlicensed prescription rates are in the range 23–62% in European paediatric hospital wards, 55–80% in neonatal intensive care units, and could be as high as 90% in the community setting.3 Wide differences in therapeutic approaches were found between and within settings and countries, suggesting the need for “harmonisation” in clinical practice.

Paediatric studies are more difficult than adult studies because of ethical, practical, and economic considerations. Attempts to improve the situation in Europe were initiated in 1997 when the Committee for Proprietary Medicinal Products (CPMP), part of the European Agency for the Evaluation of Medicinal Products (EMEA), published the “Note for guidance on clinical investigation (section III) medicinal products in the treatment of children”. This note, and the latter has been better defined through numerous studies.3 Off-label/unlicensed prescription rates are in the range 23–62% in European paediatric hospital wards, 55–80% in neonatal intensive care units, and could be as high as 90% in the community setting.3 Wide differences in therapeutic approaches were found between and within settings and countries, suggesting the need for “harmonisation” in clinical practice.

Paediatric studies are more difficult than adult studies because of ethical, practical, and economic considerations. Attempts to improve the situation in Europe were initiated in 1997 when the Committee for Proprietary Medicinal Products (CPMP), part of the European Agency for the Evaluation of Medicinal Products (EMEA), published the “Note for guidance on clinical investigation (section III) medicinal products in the treatment of children”. This note, and the latter has been better defined through numerous studies.3 Off-label/unlicensed prescription rates are in the range 23–62% in European paediatric hospital wards, 55–80% in neonatal intensive care units, and could be as high as 90% in the community setting.3 Wide differences in therapeutic approaches were found between and within settings and countries, suggesting the need for “harmonisation” in clinical practice.

Paediatric studies are more difficult than adult studies because of ethical, practical, and economic considerations. Attempts to improve the situation in Europe were initiated in 1997 when the Committee for Proprietary Medicinal Products (CPMP), part of the European Agency for the Evaluation of Medicinal Products (EMEA), published the “Note for guidance on clinical investigation (section III) medicinal products in the treatment of children”. This note, and the latter has been better defined through numerous studies.3 Off-label/unlicensed prescription rates are in the range 23–62% in European paediatric hospital wards, 55–80% in neonatal intensive care units, and could be as high as 90% in the community setting.3 Wide differences in therapeutic approaches were found between and within settings and countries, suggesting the need for “harmonisation” in clinical practice.

Paediatric studies are more dif...
Enduring memories: a paediatric gastroenterologist remembers—a tale of London and Sydney


John Walker-Smith describes himself as an inveterate collector, and in this autobiography he has drawn together his personal collection of memories, anecdotes, and most importantly people; some 400 are indexed. They are, as one would expect, mostly friends and acquaintances acquired during a distinguished career, although there is the occasional adversary or rival. For the younger reader many of the descriptions of life as a young doctor will be strikingly familiar even if separated by 30 or 40 years, while the image of early morning tea brought to one's room by a domestic, and communal roast image of early morning tea brought to one's room by a domestic, and communal roast

unthinkable. Having been a junior doctor in Sydney the author came to London to work as a houseman at the Hammersmith and Brompton hospitals. He then returned to Australia, before moving again to Zurich for further training. After this he spent five further years in Sydney before finally moving again to London to become a consultant/senior lecturer in gastroenterology at Bartholomew's and Queen Elizabeth Hospital for Children (QEH), London. Along the way he undertook his MD. This was based on an analysis of the dissecting microscope appearances of intestinal small intestine in children at postmortem examination who had died from both gastroenterological and non-gastroenterological causes. The fact that he could analyse 116 child autopsies over a period of 22 months, reflects the changing face of child health in the developed world, where diseases such as infantile gastroenteritis were frequently fatal not so many years ago, before effective oral or intravenous rehydration methods developed.

Subsequent chapters deal with issues which for many readers will be all too familiar. In the London context there is the permanent reversion of both hospital and medical school merger and restructuring which for Walker-Smith was particularly difficult. Barts merged with the Royal London and QEH closed. Then, more recently, in the last few years before retirement spent at the Royal Free, there was the controversy around the MMR vaccine and autism. It is interesting to read his perspective as someone at the very centre of events. For although he does not believe that “professional and research matters should normally be discussed in the public media”, but “should be discussed in scientific and medical media and at the relevant meetings”, the controversy has been the most widely covered of the themes running through the book is the controversy around the MMR vaccine and autism.

The final, and probably the most significant of the themes running through the book is that of the development of paediatric gastroenterology as a separate discipline within paediatrics but in an international context. There have been the technical advances from small bowel biopsy with Crosby capsule to fibreoptic endoscopy, the clinical advances in the management of failure and transplantation, and the laboratory advances in the microbiology of infections diarrhoea, and understanding of the mechanisms of mucosal inflammation. For those of us in the field this process continues. Although there have been some advances with, for example, the development of identifiable sub-specialist training schemes, many of the tensions documented in the book—specialist versus general paediatrician in academic versus clinical paediatrics, and clinical versus non-clinical research—still persist.

J M Fell

Fast facts—infant nutrition


The authors are well known for their research in infant nutrition and both have contributed to major textbooks on neonatology and the nutritional needs of preterm infants. I hoped therefore that this handbook might be the "indispensable guide to clinical practice" that it is billed to be on its front cover. As soon as the book reached me I skimmed through it, starting with the Introduction.

“Fast facts—infant nutrition provides practical, evidence based guidance to a broad range of health professionals involved in paediatrics”. Taking this statement as a starting point I decided to pose myself seven simple and basic questions that one might expect such a book to answer. How much milk does a newborn baby need? What is the energy requirement of a 6 month old baby? Does a 9 month old require vitamin supplements? When can whole cows’ milk be given? How much should a 3 month old baby weight? What sort of solids should a baby start on? How long should mothers go on breast feeding?

The answers to most of these questions were to be found, but with varying degrees of ease and difficulty. The closest I could get to how much milk a baby should take was a minimum volume of 600 ml from 4 months onwards. Neither “energy” nor “calorie” appear as headings in the index, though tables 2.3 and 2.4 and the associated text deal with their requirements. Under “multivitamins” attention is drawn to the differing recommendations in the UK (yes) and North America (no) for supplements A, C, and D after 6 months, without any evidence to explain each. However, on page 45 it is recommended, because it is not possible to identify all infants at risk of vitamin D deficiency, that supplements are prudent for breast fed term infants. Cows’ milk appears in the index but table 3.3 is the only indication, not definitive, of when it might be given alone. There are growth charts in the chapter on growth, but only as examples. None is provided for both sexes, which can be used for reference. The answer to what sort of solids to start with can be found, via the index, in the chapter on transition to solid foods. However, the most useful table (3.3) is in the chapter on growth.

Reading the book from cover to cover provides an overview of the physiology, nutritional requirements, modes of feeding of infants, and selected information on clinical and health issues. The emphasis is on healthy babies in the developed world, including preterm infants. The four fourths of children born in the developing world are largely neglected. The section on gastroenteritis properly recommends oral rehydration therapy, but there is nothing to be found on cerebral based solutions or refeeding after diarrhoea. Neither AIDS nor HIV appears in the index, even though they are mentioned as potential contraindications to breast feeding. How best to feed babies born of HIV positive mothers is a pressing problem for those who look after them.

This book is not so much “fast facts” as “ready overview”. Although it will fit in the pocket, it won’t equip the busy SHo with what he or she needs to know for the everyday problems of infant feeding and nutrition. It will however give them a useful starting point to learn more about this extremely important branch of paediatrics.

L T Weaver

References


6 Chalmers I, Hedges LV, Cooper H. A brief history of research synthesis. Eval Health Prof 2002;21(1):12–37

BOOK REVIEWS

ARCH DIS CHILD: first published as 10.1136/adc.2003.048025 on 20 August 2004. Downloaded from http://adc.bmj.com/ on September 16, 2023 by guest. Protected by copyright.